Fenton M R, Havas H F
J Immunol. 1975 Feb;114(2 pt 2):793-801.
The effect of tumor growth on serum immunoglobulin levels and on the immune response to sheep erythrocytes (SRBC) was studied in BALB/c mice bearing MOPC-315 (IgA), MOPC-460 (IgA), MOPC-173 (IgG2a) and MOPC-104E (IgM) to gain insight into the immunologic competence of the plasmacytoma-bearing host. The initial increase of myeloma protein coincided with the first appearance of the tumor and increased as the tumor progressed. However, at the time of death there was little correlation between spleen weights, tumor size, and myeloma-protein levels. The mean serum concentration of the myeloma proteins reached a higher level in the mice bearing tumors transplanted i.p. compared to those with tumors transferred subcutaneously (s.c.). Non-myeloma immunoglobulin levels in the serum were reduced: IgM was significantly lowered in the presence of MOPC-315 injected i.p. and MOPC-460 injected s.c. and the IgG2 levels were depressed in mice injected i.p. with MOPC-315 and MOPC-104E. The only significant reduction of IgA levels was seen when MOPC-173 was transplanted i.p. The decreases observed in immunoglobulin levels correlated with plasmacytoma growth. They were specific for myeloma and were not due to tumor growth per se since the levels of all immunoglobulins tested increased in the presence of Sarcoma 37, a pleomorphic neoplasm. The primary plaque-forming cell (PFC) response of tumor-bearing animals after the injection of 0.5 ml of 10% SRBC was either similar or enhanced compared to the controls. However, with a lower SRBC dosage (0.5 ml of 2% SRBC) the indirect PFC were reduced with mice bearing MOPC-104E and MOPC-173. Tumor sizes did not seem to correlate with reduction of the PFC response. MOPC-460-bearing mice had a comparable number of PFC per spleen to those of the controls, but reduced numbers when calculated per 10 spleen cells. Consistently, hemagglutination titers were reduced in all tumor-bearing animals. The number of direct and indirect PFC per spleen was increased in mice bearing Sarcoma 37, compared to the controls. The possible implications of these findings are discussed.
为深入了解携带浆细胞瘤宿主的免疫能力，在携带MOPC - 315（IgA）、MOPC - 460（IgA）、MOPC - 173（IgG2a）和MOPC - 104E（IgM）的BALB/c小鼠中，研究了肿瘤生长对血清免疫球蛋白水平以及对绵羊红细胞（SRBC）免疫反应的影响。骨髓瘤蛋白的最初增加与肿瘤的首次出现同时发生，并随着肿瘤进展而增加。然而，在死亡时，脾脏重量、肿瘤大小和骨髓瘤蛋白水平之间几乎没有相关性。与皮下（s.c.）接种肿瘤的小鼠相比，腹腔内（i.p.）接种肿瘤的小鼠中骨髓瘤蛋白的平均血清浓度达到更高水平。血清中的非骨髓瘤免疫球蛋白水平降低：腹腔内注射MOPC - 315和皮下注射MOPC - 460时，IgM显著降低；腹腔内注射MOPC - 315和MOPC - 104E的小鼠中，IgG2水平降低。仅在腹腔内移植MOPC - 173时，观察到IgA水平有显著降低。免疫球蛋白水平的降低与浆细胞瘤生长相关。它们是骨髓瘤特异性的，并非由于肿瘤本身的生长，因为在多形性肿瘤肉瘤37存在时，所有测试的免疫球蛋白水平均升高。注射0.5 ml 10% SRBC后，携带肿瘤动物的原发性噬斑形成细胞（PFC）反应与对照组相比，要么相似要么增强。然而，使用较低的SRBC剂量（0.5 ml 2% SRBC）时，携带MOPC - 104E和MOPC - 173的小鼠间接PFC减少。肿瘤大小似乎与PFC反应的降低无关。携带MOPC - 460的小鼠每个脾脏的PFC数量与对照组相当，但按每10个脾细胞计算时数量减少。同样，所有携带肿瘤的动物血凝滴度均降低。与对照组相比，携带肉瘤37的小鼠每个脾脏的直接和间接PFC数量增加。讨论了这些发现的可能意义。
